Clearmind Medicine CMND
NASDAQ CMND
$6.00 +0.01 (+0.08%)
As of: Oct 22, 2026 · 10:25 AM EDT

Clearmind Medicine (CMND) EBITDA Margin (2023 - 2024)

Updated

Clearmind Medicine's EBITDA Margin came in at -4130.04% for FY2022 (year ended Oct 31, 2022), down 1519.36 percentage points from -2610.68% in FY2021.

Analysis

Clearmind Medicine (CMND) EBITDA Margin (2023 - 2024) Analysis & Trends

  • Per Business Quant, earlier fiscal years put EBITDA Margin at -2610.68% in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,166.78 Bn 1,135.37 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 635.34 Bn 553.86 Bn 17.26 Bn 35.95%
3 AbbVie 503.48 Bn 476.60 Bn 12.70 Bn 49.01%
4 Merck 377.08 Bn 331.46 Bn 12.21 Bn 6.02%
5 Novartis Ag 304.13 Bn 268.12 Bn 11.24 Bn -
6 Astrazeneca 267.48 Bn 241.16 Bn 12.86 Bn 33.11%
7 Amgen 241.75 Bn 197.15 Bn 7.24 Bn 46.01%
8 Gilead Sciences 194.09 Bn 168.29 Bn 6.22 Bn -124.26%
9 Pfizer 172.59 Bn 119.24 Bn 10.94 Bn 39.16%
10 Clearmind Medicine 9,534.00 -39.89 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2024 -98.32%
Apr 30, 2024 -200.91%
Jul 31, 2023 -109.87%
Apr 30, 2023 -34,576.32%
Jan 31, 2023 -6,685.94%
API Access

Clearmind Medicine EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CMND&period=max&api_key=YOUR_API_KEY